Mallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge Case
Wall Street Journal – The SEC says that pharmaceutical company Mallinckrodt plc failed to tell investors it had potentially overcharged Medicaid for its flagship autoimmune drug, but waived a $40 million civil penalty.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every Brief, six days a week.